The rise of telemedicine clinics has also made it easier to access the medications, even for people who may not meet those criteria
Zhao, X
Currently, multiple phase 3 trials with oral semaglutide and orforglipron are ongoing for different populations (NCT05803421), while another oral GLP-1 RA (CT-996) is in early phase clinical trials (Table 1)
Losing muscle can lower the basal metabolic rate, potentially making long-term weight maintenance more difficulta phenomenon often described as metabolic adaptation. A functional medicine expert explains how looking at the root cause, not just symptoms, can help where conventional medicine often struggles
The GLP-1 framing isnt just marketingEriomin does appear to support GLP-1 production in studies, and the Morosil has some interesting weight loss data
Retatrutide: Why the Triple-Receptor Approach Is Getting Attention Retatrutide is attracting attention because it is being studied as a triple hormone receptor agonist